Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Other Non-Current Assets (2016 - 2025)

Capricor Therapeutics has reported Other Non-Current Assets over the past 15 years, most recently at $1.2 million for Q4 2025.

  • Quarterly results put Other Non-Current Assets at $1.2 million for Q4 2025, up 423.0% from a year ago — trailing twelve months through Dec 2025 was $1.2 million (up 423.0% YoY), and the annual figure for FY2025 was $1.2 million, up 423.0%.
  • Other Non-Current Assets for Q4 2025 was $1.2 million at Capricor Therapeutics, up from $488738.0 in the prior quarter.
  • Over the last five years, Other Non-Current Assets for CAPR hit a ceiling of $1.2 million in Q4 2025 and a floor of $88701.0 in Q1 2021.
  • Median Other Non-Current Assets over the past 5 years was $268172.0 (2022), compared with a mean of $322928.6.
  • Biggest five-year swings in Other Non-Current Assets: dropped 17.4% in 2021 and later surged 423.0% in 2025.
  • Capricor Therapeutics' Other Non-Current Assets stood at $275722.0 in 2021, then dropped by 2.74% to $268172.0 in 2022, then changed by 0.0% to $268172.0 in 2023, then dropped by 17.33% to $221700.0 in 2024, then surged by 423.0% to $1.2 million in 2025.
  • The last three reported values for Other Non-Current Assets were $1.2 million (Q4 2025), $488738.0 (Q3 2025), and $508002.0 (Q2 2025) per Business Quant data.